Editas Medicine, Inc. (EDIT): Shareholders' Equity
$27.29M
As of 2025-12-31
$105.28M
As of 2026-06-30
-57.7%
3-year compound annual growth
-41.4%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $27.29M | -79.7% | 2026-03-09, Balance as of period end |
| 2024-12-31 | $134.27M | -61.5% | 2026-03-09, Balance as of period end |
| 2023-12-31 | $349.10M | -3.2% | 2025-03-05, Balance as of period end |
| 2022-12-31 | $360.68M | -34.9% | 2025-03-05, Balance as of period end |
| 2021-12-31 | $553.64M | +40.7% | 2024-02-28, Balance as of period end |
| 2020-12-31 | $393.59M | +50.0% | 2023-02-22, Balance as of period end |
| 2019-12-31 | $262.44M | +11.1% | 2022-02-24, Balance as of period end |
| 2018-12-31 | $236.16M | +13.5% | 2021-02-26, Balance as of period end |
| 2017-12-31 | $208.08M | +54.6% | 2020-02-26, Balance as of period end |
| 2016-12-31 | $134.61M | n/m | 2019-03-01, Balance as of period end |
| 2015-12-31 | -$83.11M | n/m | 2018-03-08, Balance as of period end |
| 2014-12-31 | -$15.29M | n/a | 2017-03-03, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $27.29M | -79.7% |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $196.08M | -34.6% |
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | -$14.27M | n/m |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | $1.58B | +89.0% |
| Fennec Pharmaceuticals Inc. (FENC) | 2025-12-31 | $35.47M | n/m |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $256.59M | +18.8% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $186.29M | +741.1% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $92.25M | +63.6% |
| Protalix BioTherapeutics, Inc. (PLX) | 2025-12-31 | $48.23M | +11.6% |
Compare EDIT, VYGR, SGMOQ, KYMR side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗